Page last updated: 2024-11-02

pioglitazone and Eosinophilic Esophagitis

pioglitazone has been researched along with Eosinophilic Esophagitis in 1 studies

Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.

Eosinophilic Esophagitis: Chronic ESOPHAGITIS characterized by esophageal mucosal EOSINOPHILIA. It is diagnosed when an increase in EOSINOPHILS are present over the entire esophagus. The reflux symptoms fail to respond to PROTON PUMP INHIBITORS treatment, unlike in GASTROESOPHAGEAL REFLUX DISEASE. The symptoms are associated with IgE-mediated hypersensitivity to food or inhalant allergens.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Nhu, QM1
Hsieh, L1
Dohil, L1
Dohil, R1
Newbury, RO1
Kurten, R1
Moawad, FJ1
Aceves, SS1

Other Studies

1 other study available for pioglitazone and Eosinophilic Esophagitis

ArticleYear
Antifibrotic Effects of the Thiazolidinediones in Eosinophilic Esophagitis Pathologic Remodeling: A Preclinical Evaluation.
    Clinical and translational gastroenterology, 2020, Volume: 11, Issue:4

    Topics: Biopsy; Budesonide; Cells, Cultured; Drug Evaluation, Preclinical; Eosinophilic Esophagitis; Esophag

2020